Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

Ona Therapeutics United Kingdom United States of America Spain

Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory BoardDr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial OfficerAccelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on eliminating hard-to-treat resistant cancer cells View original content:https://www.prnewswire.co.uk/news-releases/ona-therapeutics-strengthens-leadership-team-to-accelerate-first-in-class-adcs-into-clinical-development-across-cancer-types-302379077.html